Practical considerations in medical cannabis administration and dosing

European Journal of Internal Medicine

Volumn 49, Issue , 2018, Pages 12-19

  MacCallum, Caroline A ^a   Russo, Ethan B ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b International Cannabis and Cannabinoids Institute (ICCI)   (Czech Republic)

Author keywords

Adverse events; Cannabinoids; Cannabis; Drug abuse; Marijuana; Psychopharmacology

Indexed keywords

CANNABIDIOL; MEDICAL CANNABIS; TETRAHYDROCANNABINOL; CANNABIS; DRONABINOL; NABIXIMOLS;

ANXIETY; ANXIETY DISORDER; ATAXIA; BLURRED VISION; BRONCHITIS; CANCER PALLIATIVE THERAPY; CHRONIC PAIN; COUGHING; DEPRESSION; DIARRHEA; DROWSINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG METABOLISM; EPILEPSY; FATIGUE; GOOD CLINICAL PRACTICE; GOOD MANUFACTURING PRACTICE; HEADACHE; HEALTH CARE QUALITY; HUMAN; MALIGNANT NEOPLASM; NAUSEA; NEUROLOGIST; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT MONITORING; PEDIATRICS; PHARMACOKINETIC PARAMETERS; PRESCRIPTION; PSYCHOSIS; REVIEW; SMOKING; TACHYCARDIA; XEROSTOMIA; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; INFLAMMATION; PAIN;

CANNABIDIOL; CANNABIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HUMANS; INFLAMMATION; MEDICAL MARIJUANA; PAIN;

EID: 85039922237     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2018.01.004     Document Type: Review

References (83)

1. Russo, E.B., The pharmacological history of Cannabis. Pertwee, R., (eds.) Handbook of cannabinoids, 2014, Oxford University Press, Oxford, United Kingdom, 23–43.
2. Russo, E.B., History of cannabis and its preparations in saga, science and sobriquet. Chem Biodivers 4 (2007), 2624–2648.
3. Pacher, P., Batkai, S., Kunos, G., The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 (2006), 389–462.
4. Evanoff, A.B., Quan, T., Dufault, C., Awad, M., Bierut, L.J., Physicians-in-training are not prepared to prescribe medical marijuana. Drug Alcohol Depend 180 (2017), 151–155.
5. Frieden, T.R., Evidence for health decision making - beyond randomized, controlled trials. N Engl J Med 377 (2017), 465–475.
6. Upton, R., Craker, L., ElSohly, M., Romm, A., Russo, E., Sexton, M., Cannabis inflorescence: Cannabis spp.: standards of identity, analysis and quality control. 2013, Scotts Valley, CA, USA, American Herbal Pharmacopoeia.
7. Russo, E.B., Current therapeutic cannabis controversies and clinical trial design issues. Front Pharmacol, 7, 2016, 309.
8. Russo, E.B., Marcu, J., Cannabis pharmacology: the usual suspects and a few promising leads. Adv Pharmacol 80 (2017), 71–138.
9. Di Marzo, V., Melck, D., Bisogno, T., De Petrocellis, L., Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21 (1998), 521–528.
10. Laprairie, R.B., Bagher, A.M., Kelly, M.E., Denovan-Wright, E.M., Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172 (2015), 4790–4805.
11. Russo, E.B., Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163 (2011), 1344–1364.
12. Lewis, M.A., Russo, E.B., Smith, K.M., Pharmacological foundations of Cannabis chemovars: no “strain” no gain. Planta Med, 2017, 10.1055/s-0043-122240 [in press, PubMed: https://www.ncbi.nlm.nih.gov/pubmed/?term=Russo+Lewis+chemovars].
13. Potter, D.J., Clark, P., Brown, M.B., Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53 (2008), 90–94.
14. Mehmedic, Z., Chandra, S., Slade, D., Denham, H., Foster, S., Patel, A.S. et al., Potency trends of delta(9)-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55:5 (2010), 1209–1217.
15. Verhoeckx, K.C., Korthout, H.A., van Meeteren-Kreikamp, A.P., Ehlert, K.A., Wang, M., van der Greef, J. et al., Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 6 (2006), 656–665.
16. Rock, E.M., Sticht, M.A., Parker, L.A., Effects of phytocannabinoids on nausea and vomiting. Pertwee, R.G., (eds.) Handbook of cannabis, 2014, Oxford University Press, Oxford, UK, 435–454.
17. Nadal, X., Del Rio, C., Casano, S., Palomares, B., Ferreiro-Vera, C., Navarrete, C. et al., Tetrahydrocannabinolic acid is a potent PPARgamma agonist with neuroprotective activity. Br J Pharmacol 174:23 (2017), 4263–4276.
18. Sulak, D., Saneto, R., Goldstein, B., The current status of artisanal Cannabis for the treatment of epilepsy in the United States. Epilepsy Behav 70 (2017), 328–333.
19. Bolognini, D., Rock, E.M., Cluny, N.L., Cascio, M.G., Limebeer, C.L., Duncan, M. et al., Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168 (2013), 1456–1470.
20. Rock, E.M., Limebeer, C.L., Petrie, G.N., Williams, L.A., Mechoulam, R., Parker, L.A., Effect of prior foot shock stress and Delta9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats. Psychopharmacology (Berl) 234 (2017), 2207–2217.
21. Huestis, M.A., Human cannabinoid pharmacokinetics. Chem Biodivers 4 (2007), 1770–1804.
22. Russo, E.B., Hohmann, A.G., Role of cannabinoids in pain management. Deer, T., Gordin, V., (eds.) Comprehensive treatment of chronic pain by medical, interventional and behavioral approaches, 2013, Springer, New York, 181–197.
23. Tashkin, D.P., Effects of marijuana smoking on the lung. Ann Am Thorac Soc 10 (2013), 239–247.
24. Abrams, D.I., Vizoso, H.P., Shade, S.B., Jay, C., Kelly, M.E., Benowitz, N.L., Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 82 (2007), 572–578.
25. Bloor, R.N., Wang, T.S., Spanel, P., Smith, D., Ammonia release from heated ‘street’ cannabis leaf and its potential toxic effects on cannabis users. Addiction 103 (2008), 1671–1677.
26. Earleywine, M., Smucker, Barnwell S., Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduct J, 4, 2007, 11.
27. Loflin, M., Earleywine, M.A., New method of cannabis ingestion: the dangers of dabs?. Addict Behav 39 (2014), 1430–1433.
28. National Academies of Sciences Engineering and Medicine (U.S.), Committee on the health effects of marijuana: an evidence review and research agenda. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. 2017, the National Academies Press, Washington, DC, 1 (online resource, xviii, 468 pages).
29. Devinsky, O., Cross, J.H., Laux, L., Marsh, E., Miller, I., Nabbout, R. et al., Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 376 (2017), 2011–2020.
30. Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C. et al., Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry, 2, 2012, e94.
31. Hill, M.N., Bierer, L.M., Makotkine, I., Golier, J.A., Galea, S., McEwen, B.S. et al., Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology 38 (2013), 2952–2961.
32. Volicer, L., Stelly, M., Morris, J., McLaughlin, J., Volicer, B.J., Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 12 (1997), 913–919.
33. Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., de Oliveira, D.C., De Martinis, B.S., Kapczinski, F. et al., Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36 (2011), 1219–1226.
34. Ware, M.A., Wang, T., Shapiro, S., Collet, J.P., team Cs, Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain 16 (2015), 1233–1242.
35. Russo, E.B., Mathre, M.L., Byrne, A., Velin, R., Bach, P.J., Sanchez-Ramos, J. et al., Chronic cannabis use in the compassionate investigational new drug program: an examination of benefits and adverse effects of legal clinical cannabis. J Cannabis Ther 2 (2002), 3–57.
36. Russo, E., Cannabis treatments in obstetrics and gynecology: a historical review. J Cannabis Ther 2 (2002), 5–35.
37. Grant, K.S., Petroff, R., Isoherranen, N., Stella, N., Burbacher, T.M., Cannabis use during pregnancy: pharmacokinetics and effects on child development. Pharmacol Ther, 2017, 10.1016/j.pharmthera.2017.08.014 [in press].
38. Conner, S.N., Bedell, V., Lipsey, K., Macones, G.A., Cahill, A.G., Tuuli, M.G., Maternal marijuana use and adverse neonatal outcomes: a systematic review and meta-analysis. Obstet Gynecol 128 (2016), 713–723.
39. Sellers, E.M., Schoedel, K., Bartlett, C., Romach, M., Russo, E.B., Stott, C.G. et al., A multiple-dose, randomized, double-blind, placebo-controlled, parallel-group QT/QTc study to evaluate the electrophysiologic effects of THC/CBD spray. Clin Pharmacol Drug Dev 2 (2013), 285–294.
40. Herkenham, M., Lynn, A.B., Little, M.D., Johnson, M.R., Melvin, L.S., de Costa, B.R. et al., Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87 (1990), 1932–1936.
41. Wang, T., Collet, J.P., Shapiro, S., Ware, M.A., Adverse effects of medical cannabinoids: a systematic review. CMAJ 178 (2008), 1669–1678.
42. Russo, E.B., Etges, T., Stott, C., Wright, S., Mohammed, A., Robson, P., Sativex safety profile is improving over time. 21st Annual Symposium on the Cannabinoids. 2011, International Cannabinoid Research Society, St. Charles, IL, USA, GW1.
43. Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O. et al., A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R))), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18 (2011), 1122–1131.
44. Favrat, B., Menetrey, A., Augsburger, M., Rothuizen, L., Appenzeller, M., Buclin, T. et al., Two cases of “cannabis acute psychosis” following the administration of oral cannabis. BMC Psychiatry, 5, 2005, 17.
45. Zendulka, O., Dovrtelova, G., Noskova, K., Turjap, M., Sulcova, A., Hanus, L. et al., Cannabinoids and cytochrome P450 interactions. Curr Drug Metab 17 (2016), 206–226.
46. Stott, C., White, L., Wright, S., Wilbraham, D., Guy, G.A., Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. 2, 2013, SpringerPlus, 236.
47. Ujvary, I., Hanus, L., Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res 1 (2016), 90–101.
48. Wade, D.T., Makela, P.M., House, H., Bateman, C., Robson, P.J., Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12 (2006), 639–645.
49. Notcutt, W., Langford, R., Davies, P., Ratcliffe, S., Potts, R., A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). Mult Scler 18 (2012), 219–228.
50. Serpell, M.G., Notcutt, W., Collin, C., Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 260 (2013), 285–295.
51. Russo, E.B., Cannabis and epilepsy: an ancient treatment returns to the fore. Epilepsy Behav 70 (2017), 292–297.
52. Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J. et al., Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15 (2016), 270–278.
53. Russo, E.B., Guy, G.W., Robson, P.J., Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers 4 (2007), 1729–1743.
54. Johnson, J.R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E.D., Potts, R., Fallon, M.T., Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39 (2010), 167–179.
55. Portenoy, R.K., Ganae-Motan, E.D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S. et al., Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13 (2012), 438–449.
56. Guzman, M., Duarte, M.J., Blazquez, C., Ravina, J., Rosa, M.C., Galve-Roperh, I. et al., A pilot clinical study of delta(9)-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 95 (2006), 197–203.
57. Foroughi, M., Hendson, G., Sargent, M.A., Steinbok, P., Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas–possible role of Cannabis inhalation. Childs Nerv Syst 27 (2011), 671–679.
58. Singh, Y., Bali, C., Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation. Case Rep Oncol 6 (2013), 585–592.
59. GW Pharmaceuticals, GW pharmaceuticals achieves positive results in phase 2 proof of concept study in glioma. 2017.
60. Torres, S., Lorente, M., Rodriguez-Fornes, F., Hernandez-Tiedra, S., Salazar, M., Garcia-Taboada, E. et al., A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10 (2011), 90–103.
61. Caffarel, M.M., Andradas, C., Mira, E., Perez-Gomez, E., Cerutti, C., Moreno-Bueno, G. et al., Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer, 9, 2010, 196.
62. Holdcroft, A., Maze, M., Dore, C., Tebbs, S., Thompson, S., A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 104 (2006), 1040–1046.
63. Hampson, A.J., Grimaldi, M., Axelrod, J., Wink, D., Cannabidiol and (−)delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95 (1998), 8268–8273.
64. Fernandez-Ruiz, J., Moreno-Martet, M., Rodriguez-Cueto, C., Palomo-Garo, C., Gomez-Canas, M., Valdeolivas, S. et al., Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 163 (2011), 1365–1378.
65. Venderova, K., Ruzicka, E., Vorisek, V., Visnovsky, P., Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. Mov Disord, 19, 2004, 1102.
66. Wong, S.S., Wilens, T.E., Medical cannabinoids in children and adolescents: a systematic review. Pediatrics, 140(5), 2017, 10.1542/peds.2017-1818 pii: e20171818.
67. Lorenz, R., On the application of cannabis in paediatrics and epileptology. Neuroendocrinol Lett, 25, 2004 [In Press].
68. Gottschling, S., Cannbinoide bei Kindern. Gute Erfahrungen bei Schmerzen, Spastik und in der Onkologie. Angewandte Schmerztherapie und Palliativmedizin. 2011, 55–57.
69. Abrahamov, A., Mechoulam, R., An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56 (1995), 2097–2102.
70. Muller-Vahl, K.R., Emrich, H.M., Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother 8 (2008), 1037–1048.
71. Robson, P.J., Guy, G.W., Di Marzo, V., Cannabinoids and schizophrenia: therapeutic prospects. Curr Pharm Des 20 (2014), 2194–2204.
72. Russo, E.B., Handbook of psychotropic herbs: A scientific analysis of herbal remedies for psychiatric conditions. 2001, Haworth Press, Binghamton, NY.
73. Russo, E.B., The role of cannabis and cannabinoids in pain management. Cole, B.E., Boswell, M., (eds.) Weiner's pain management: a practical guide for clinicians, 7th ed., 2006, CRC Press, Boca Raton, FL, 823–844.
74. Cichewicz, D.L., Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74 (2004), 1317–1324.
75. Lucas, P., Walsh, Z., Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy 42 (2017), 30–35.
76. Reiman, A., Cannabis as a substitute for alcohol and other drugs. Harm Reduct J, 6, 2009, 35.
77. Haroutounian, S., Ratz, Y., Ginosar, Y., Furmanov, K., Saifi, F., Meidan, R. et al., The effect of medicinal cannabis on pain and quality of life outcomes in chronic pain: a prospective open-label study. Clin J Pain 32:12 (2016), 1036–1043.
78. Bachhuber, M.A., Saloner, B., Cunningham, C.O., Barry, C.L., Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 174 (2014), 1668–1673.
79. Bradford, A.C., Bradford, W.D., Medical marijuana laws reduce prescription medication use in Medicare part D. Health Aff (Millwood) 35 (2016), 1230–1236.
80. Bradford, A.C., Bradford, W.D., Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Aff (Millwood) 36 (2017), 945–951.
81. Johnson, J.R., Lossignol, D., Burnell-Nugent, M., Fallon, M.T., An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 46 (2013), 207–218.
82. Abrams, D.I., Couey, P., Shade, S.B., Kelly, M.E., Benowitz, N.L., Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 90 (2011), 844–851.
83. Rekand, T.T.H.C., CBD spray and MS spasticity symptoms: data from latest studies. Eur Neurol 71:Suppl. 1 (2014), 4–9.